CFDE Data Portal | Search MARVELD2

	Label	Description
	MARVELD2 associations Collection (Entity type)	Associations for MARVELD2_associations
	MARVELD2 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	MARVELD2 Gene (Entity type)	ENSG00000274671 - MARVEL domain containing 2 [Source:HGNC Symbol;Acc:HGNC:26401]
	MARVELD2 Gene (Entity type)	ENSG00000152939 - MARVEL domain containing 2
	GSE239844 crizotinib 6 v 9 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE96649 1 V 0 DEXAMETHASONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE125211 0 V 1 NICOTINAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 4 v 10 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE48812 sulforaphane 8 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

MARVELD2 associations

Associations for MARVELD2_associations

MARVELD2 associations.tsv

A file from IDG as part of the Harmonizome project

MARVELD2

ENSG00000274671 - MARVEL domain containing 2 [Source:HGNC Symbol;Acc:HGNC:26401]

MARVELD2

ENSG00000152939 - MARVEL domain containing 2

GSE239844 crizotinib 6 v 9 human up

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE96649 1 V 0 DEXAMETHASONE HUMAN DN

A Gene Set from LINCS

GSE125211 0 V 1 NICOTINAMIDE MOUSE UP

A Gene Set from LINCS

GSE48812 sulforaphane 4 v 10 human dn

A Gene Set from LINCS

GSE48812 sulforaphane 8 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.